Elderly patients with stage I-III non-small-cell lung cancer (NSCLC) constitute a peculiar patient population and need specific therapeutic approaches. Limited resections are an attractive alternative for elderly patients with resectable NSCLC because of the potential reduction in postoperative complications. Curative radiation therapy is an acceptable alternative for elderly patients who are unfit for or refuse surgery. Hypofractionated stereotactic body radiation therapy is of particular interest for this population because of its favorable tolerance. Elderly patients may tolerate chemotherapy poorly because of comorbidity and organ failure. The survival benefit obtained with adjuvant platinum-based chemotherapy in the younger population may vanish or decrease in the elderly because of a potential higher toxic death rate or lower compliance to treatment. The efficacy and feasibility of adjuvant chemotherapy for elderly patients need to be investigated in specific trials. Neoadjuvant chemotherapy remains an experimental approach under investigation in the general patient population, and consequently should not be considered in clinical practice in the elderly. Retrospective analyses on chemoradiation in elderly patients should be considered globally ambiguous and at risk of selection bias. Only specifically designed prospective studies will elucidate the real role and feasibility of this combined approach in the treatment of unselected elderly patients.
More than two-thirds of the patients who die of lung cancer in the United States are over 65 years old. Specific approaches to the treatment of elderly patients with non-small-cell lung cancer (NSCLC) are needed. In fact, many elderly patients tolerate all treatment modalities poorly because of comorbidity and organ failure. The prevalence of these comorbid conditions is about twice as high as in the general population. The most important coexisting pathologies in lung cancer patients are cardiovascular and pulmonary diseases, which are common among heavy cigarettes smokers. Moreover, among elderly persons it is common to find a condition known as "frailty," in which most functional reserve is exhausted. Decreased hepatic, renal, and bone marrow functions have a negative impact on the degree of toxicity—in particular, on cisplatin toxicity. In order to plan the treatment of elderly NSCLC patients, a multidimensional geriatric evaluation, including not only assessment of comorbidities but also of functional, mental, and nutritional status, is needed.
The dilemma that elderly patients with lung cancer and their physicians face is that of balancing the increased risk of surgery with conventional open thoracotomy techniques and improved long-term survival when surgery is successful. Twenty-five years ago, several authors concluded that age beyond 70 years was a prohibitory factor for thoracotomy. Although small series have since suggested that carefully selected elderly patients can safely undergo thoracotomy, it is still common practice to provide fewer surgical options to the elderly patient with lung cancer.
Nugent et al came to this conclusion after reporting data from a series of 1,802 patients collected in the United States from 1983 to 1993. Although the incidence of stage I-II cancer was five times higher in the elderly group (6% among younger patients and 33% among older patients), the resection rate was 32% for the younger group and only 6% for the elderly. Similarly, in Europe, Damhuis and Schutte found a 26% resection rate for patients who had lung cancer and were younger than 70 years, compared with a 14% rate for those who were older than 70 years. Both groups in this report had comparable operative mortality (3.2% vs 4.0%), probably indicating careful preoperative selection of elderly patients.
Some authors believe that many elderly patients who have lung cancer and undergo standard anatomic pulmonary resections (lobectomy or pneumonectomy) with posterolateral thoracotomy have a higher incidence of postoperative mortality than younger individuals. The Lung Cancer Study Group (LCSG) quantified this observation in a multi-institutional study conducted in the late 1970s and early 1980s. Patients who were aged 70 years or older had a 30-day postoperative mortality of 7.1% compared with 1.3% for patients who were younger than 60 years and 4.1% for those between ages 60 and 69 years.
In 14 reports from Italy, the United Kingdom, the United States, and Finland published after the LCSG data, the operative mortality after lung resection with an open thoracotomy technique has ranged from 1% to 22%, with an average of 5.9%. These data compare poorly with video-assisted thoracic surgery (VATS) techniques for removal of stage I lung cancer in elderly patients. In six recent reports of 378 patients from Canada, the United States, Japan, and Hong Kong, the average operative mortality was 1.1%.
The operative risk of death after thoracotomy in elderly patients is due to two major anatomic changes: loss of functional lung tissue and temporary impairment of the ipsilateral muscles of respiration. To serve these impaired patients with otherwise resectable lung cancer, lesser operations such as segmentectomy and wedge resection are increasingly being performed, especially among elderly patients. Lung-sparing procedures such as segmentectomy better preserve lung function than lobectomy. These procedures are also associated with less operative morbidity and mortality compared with lobectomy but, like lumpectomy, may be associated with a higher local recurrence rate.
A multi-institutional, prospective, randomized phase III trial compared lobectomy by open thoracotomy with limited resections, also by open thoracotomy. Limited resections included both segmentectomy and open wedge resection. Although there was no significant overall difference in postoperative complications and mortality, 6 of 125 patients who received lobectomy and none of the 122 patients who received limited resection developed respiratory failure. The major finding of this study was that limited resections were associated with a higher incidence of local recurrence within the chest compared with lobectomies (P = .02, one-tailed). Thus, this study has established that lobectomy remains the gold standard of surgical resection for patients who can tolerate the procedure. The difference in local recurrence, however, did not translate into a statistical difference for long-term survival (P = .088, one-tailed). Furthermore, with special regard to elderly patients, the survival curves of the two groups were nearly identical for the first 3 years after surgery.
On the basis of these data, some authors have shown an institutional bias toward wedge resection for elderly patients with early-stage lung cancer.[7,11] Limited resections are an attractive alternative for elderly patients with lung cancer because of the potential reduction in postoperative complications, the rapid recovery, and the increased prevalence of early-stage disease in this group. Because long-term survival is the same after lobectomy or limited resection for the first several postoperative years, the elderly, with a lower remaining life expectancy than younger patients, may benefit the most from this strategy. Some authors believe that there is an age above which lobectomy is no longer the gold standard.
Mery et al confirmed the hypothesis that at some threshold of age, lobectomy no longer provides a population survival advantage. In fact, analyzing the Surveillance, Epidemiology, and End Results database, these investigators showed that for patients who are 74 years or younger, the survival curves between lobectomy and limited resection diverge after 25 months. Overall median survival after lobectomy was 66 months, compared with 50 months after limited resection (P < .0001). Kaplan-Meier curves for long-term survival after limited resection and lobectomy among patients who were 75 years or older, however, never deviated from each other.
Patients who are unfit for surgery or refuse surgery are typically treated with radiation therapy, which has shown 5-year survival rates of 5% to 30%.[16,17] Although some patients are not offered therapy because of comorbid disease or advanced age, in a review by McGarry et al, cancer was the cause of death for 53% of inoperable patients who received no specific cancer therapy at time of diagnosis for stage I NSCLC. Poor performance status and comorbid conditions that preclude surgery at least partially account for the poor survival of patients with early-stage lung cancer treated with radiotherapy. Complication rates of definitive radiation therapy are low, despite poor pulmonary function and performance status.
Pergolizzi et al performed a prospective study on curative radiotherapy alone in 40 elderly patients with stage IIIA disease. Radiotherapy was directed toward gross tumor burden with a median of 60 Gy (conventionally fractionated). No treatment-related mortality was observed, and no clinically significant acute morbidity was scored. The median survival was 19 months and the 5-year survival rate was 12%.
Several retrospective studies have been reported on radiotherapy as curative treatment of unresectable NSCLC in elderly patients, and globally, such treatment was well tolerated by this older population. Zachariah et al reported on radiotherapy in lung cancer in patients ? 80 years old. Of 36 patients, 21 were treated with conventional radiotherapy doses ranging from 59.40 to 66 Gy. Response to radiotherapy was observed in 9 patients (43%). The treatment was well tolerated by this very old population. In a study by Gava et al, for 38 patients aged at least 70 years with locally advanced disease, the 1-year survival rate approached 44%.
Lonardi et al treated 48 elderly (≥ 75 years) patients with stage IIIA or IIIB, inoperable, symptomatic NSCLC using 1.8 to 2.5 Gy per fraction to a median dose of 50 Gy. These investigators observed a 2-year survival rate of 10% and a median survival of 5 months. Of 47 assessable patients, 21 had a partial remission, 17 stable disease, and 9 had progressive disease. Despite the short overall median survival, dose-related survival was much better in patients given at least 50 Gy than in those treated with lower doses: 52% vs 35% at 6 months, and 28% vs 4% at 13 months. Most symptoms were successfully palliated. Toxicity was negligible, mainly consisting of World Health Organization (WHO) grade 1/2 esophagitis.
Tombolini et al used radiotherapy alone in 41 patients ≥ 70 years with medically inoperable IIIA and IIIB NSCLC. These patients received a conventionally fractionated radiotherapy dose of 50 to 60 Gy plus a 10-Gy boost to the gross tumor volume. Two-year survival and disease-free survival rates were 27% and 14.6%, respectively.
Thus, although at least two studies have found advanced age to be a negative prognostic factor for stage I disease,[17,24] the toxicity of radiation therapy alone for inoperable lung cancer in elderly patients is not greater than toxicity in younger patients.[25,26] It is interesting to note that Gauden and Tripcony showed a general trend for elderly patients (≥ 70 years vs < 70 years) to have better 5-year survival (34% vs 22%), median survival (26 vs 22 months), and recurrence-free survival (30% vs 18%). The cohort of patients aged 80 years or older had the smallest proportion of medical disease precluding surgery (53%) and the largest proportion with good performance status (80%). Good performance status and fewer comorbid conditions may explain the trend for a favorable outcome in the older patient subgroup.
Dr. Gridelli is a speaker and consultant for Eli Lilly and Roche, and a speaker for Pierre Fabre.
1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003.
2. Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, et al: Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 21:105-113, 1998.
3. Weiss W: Operative mortality and five year survival rates in patients with bronchogenic carcinoma. Am J Surg 128:799-804, 1974.
4. PaolaCiriaco A, Pugliesi A, Carretta B, et al: Is surgery for non-small cell lung cancer justified in patients over 70 years of age? Chest 110:214S, 1996.
5. Nugent W, Dunty M, Hammerness P, et al: Non-small cell lung cancer at the extremes of age: Impact on diagnosis and treatment. Ann Thorac Surg 63:193-197, 1997.
6. Damhuis RA, Wereldsma JC, Wiggers T: The influence of age on resection rates and postoperative mortality in 6457 patients with colorectal cancer. Int J Colorectal Dis 11:45-48, 1996.
7. Jaklitsch MT, Wiener DC, Colson YL: Thoracic surgical options for elderly patients with lung cancer. ASCO Educational Book, pp 592-604, 2005.
8. Ginsberg R, Hill L, Eagan R, et al: Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 86:654-658, 1983.
9. Cummings SR, Lillington GA, Richard RJ: Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach. Am Rev Respir Dis 134:449-452, 1986.
10. Jaklitsch MT, Pappas-Estocin A, Bueno R: Thoracoscopic surgery in elderly lung cancer patients. Crit Rev Oncol Hematol 49:165-171, 2004.
11. Jaklitsch M, Mery C, Bueno R, et al: Lesser pulmonary resections are more common in elderly non-small cell lung cancer patients but do not adversely affect survival (abstract 1819). Proc Am Soc Clin Oncol 18:471a, 1999.
12. Keenan R, Landrenau R, Maley RH Jr, et al: Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg 78:228-233, 2004.
13. Jaklitsch MT, DeCamp MM Jr, Liptay MJ, et al: Video-assisted thoracic surgery in the elderly: A review of 307 cases. Chest 110:751-758, 1996.
14. Ginsberg R, Rubinstein L: Randomized trial of lobectomy vs limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 78:228-233, 2004.
15. Mery C, Pappas A, Lukanich J, et al: Long-term survival of patients with early-stage non-small cell lung cancer as a function of age and treatment modality. Chest 120:176S, 2001.
16. Gore EM: Radiation therapy of lung cancer in elderly patients. ASCO Educational Book, pp 605-610, 2005.
17. Sibley GS, Jamieson T, Marks L, et al: Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys 40:149-154, 1998.
18. McGarry RC, Song G, des Rosiers P, et al: Observation-only management of early stage, medically inoperable lung cancer: Poor outcomes. Chest 121:1155-1158, 2002.
19. Pergolizzi S, Santacaterina A, De Renzis C, et al: Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study. Lung Cancer 37:201-206, 2002.
20. Zachariah B, Balducci L, Venkattaramanabalaji GV, et al: Radiotherapy for cancer patients age 80 or older: A study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 39:1125-1129, 1997.
21. Gava A, Bertossi L, Zorat PL, et al: Radiotherapy in the elderly with lung carcinoma: the experience of the Italian "Geriatric Radiation Oncology Group". Rays 22(suppl 1):61-65, 1997.
22. Lonardi F, Coeli M, Pavanato G, et al: Radiotherapy for non-small cell lung cancer in patients aged 75 and over: Safety, effectiveness and possible impact on survival. Lung Cancer 28(1):43-50, 2000.
23. Tombolini V, Bonanni A, Donato V, et al: Radiotherapy alone in elderly patients with medically inoperable stage IIIA and IIIB non-small cell lung cancer. Anticancer Res 20(6C):4829-4833, 2000.
24. Kaskowitz L, Graham MV, Emami B, et al: Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 27:517-523, 1993.
25. Pignon T, Gregor A, Scaake Koning C, et al: Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 46:239-248, 1998.
26. Gauden SJ, Tripcony L: The curative treatment by radiation therapy for stage I non-small cell lung cancer in a geriatric population. Lung Cancer 32:71-79, 2001.
27. Bradley JD, Graham MV, Winter KW, et al: Acute and late toxicity results of RTOG 9311: A dose escalation study using 3D conformal radiation therapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 57(suppl 2):S137-138, 2003.
28. Timmerman R, Papiez L, McGarry R, et al: Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer patients. Chest 124:1946-1955, 2003.
29. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999.
30. Gridelli C, Perrone F, Gallo C, et al, for the MILES Investigators: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003.
31. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002.
32. Langer CJ, Vangel M, Schiller J, et al: Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (< 70) (abstract 2571). Proc Am Soc Clin Oncol 22:639, 2003.
33. Kelly K, Giarritta S, Hayes S, et al: Should older patients receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308 (abstract 1313). Proc Am Soc Clin Oncol 20:329a, 2001.
34. Belani CP, Fossella FV: Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin vs vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: Analyses in elderly patients. Lung Cancer 41(suppl 2):S18, 2003.
35. Lilenbaum RC, Herndon JE, List M, et al: Single-agent vs combination chemotherapy in advanced non-small cell lung cancer: A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. J Clin Oncol 23:190-196, 2005.
36. Hensing TA, Peterman AH, Schell MJ, et al: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV non small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98:779-788, 2003.
37. Perrone F, Gallo C, Gridelli C: Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:1029-1031, 2002.
38. Feliu J, Martin G, Madronal C, et al: Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 52:247-252, 2003.
39. Maestu I, Gomez-Aldaravi L, Torregrosa MD, et al: Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42:345-354, 2003.
40. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995.
41. Scagliotti GV, Fossati R, Torri V, et al: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95:1422-1424, 2003.
42. Waller D, Peake MD, Stephens RJ, et al: Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26:173-182, 2004.
43. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
44. Winton TL, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005.
45. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7019). J Clin Oncol 23(14S): 621s, 2004.
46. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004.
47. Hamada C, Ohta M, Wada H, et al: Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer (abstract 70). Proc Am Soc Clin Oncol 23(14S):617s, 2004.
48. Hotta K, Matsuo K, Ueoka H, et al: Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22:3860-3867, 2004.
49. Depierre A, Milleron B, Moro-Sibilot D, et al: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20:247-253, 2002.
50. Pisters K, Vallieres E, Bunn P, et al: S9900: A phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin chemotherapy in early stage non-small cell lung cancer: Preliminary results (abstract LBA7012). J Clin Oncol 23(16S):1095s, 2005.
51. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17:2692-2699, 1999.
52. Curran WJ Jr, Scott CB, Langer CJ, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 (abstract 2499). Proc Am Soc Clin Oncol 22:621, 2003.
53. Atagi S, Kawahara M, Ogawara M, et al: Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 30:59-64, 2000.
54. D'Angelillo RM, Trodella L, Ramella S, et al Neoadjuvant chemoradiotherapy followed by surgery in elderly patients with locally advanced non-small cell lung cancer: Analysis of feasibility, toxicity and factors predicting surgical resection and survival (abstract 7167). Proc Am Soc Clin Oncol 23:654, 2004.
55. Movsas B, Scott C, Sause W, et al: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45:1143-1149, 1999.
56. Werner-Wasik M, Scott C, Cox JD, et al: Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48:1475-1482, 2000.
57. Langer C, Scott C, Byhardt R, et al: Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC. Lung Cancer 29(suppl 1):119, 2000.
58. Langer CJ, Hsu C, Curran WJ, et al: Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10 (abstract 1193). Proc Am Soc Clin Oncol 21:299a, 2002.
59. Schild SE, Stella PJ, Geyer SM, et al: North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201-3206, 2003.